GE HealthCare’s agreement with CardioNavix, a part of the CDL Nuclear Technologies services group, further broadens the reach of Flyrcado.
GE HealthCare announced a Distribution and Services Agreement (DSA) with CardioNavix, a part of the CDL Nuclear Technologies services group that provides end-to-end cardiac positron emission tomography (PET) imaging solutions to hospitals and outpatient practices throughout the U.S. Through this agreement, GE HealthCare aims to bring Flyrcado (flurpiridaz F18) injection, its novel cardiac PET imaging agent, to patients nationwide, including private cardiology practices and office and hospital imaging settings, expanding the reach of cardiac PET for the evaluation of known or suspected coronary artery disease.
Health Technology Insights: Exxat and Powerback Rehab Partner to Enhance Clinical Education
Around six million myocardial perfusion imaging (MPI) procedures are performed each year in the U.S. Within that total, PET MPI represents roughly five to ten percent, and is increasingly utilized by U.S. cardiology practices. By strengthening delivery in office-based care, this collaboration is expected to accelerate adoption of Flyrcado, which in the multi-center international Phase III AURORA trial demonstrated higher diagnostic efficacy versus SPECT MPI for detecting coronary artery disease.4
“This collaboration with CardioNavix is an important step in making Flyrcado available for patients nationwide, across all sites of care,” said Eric Ruedinger, vice president and general manager of GE HealthCare’s Pharmaceutical Diagnostics division for the U.S. and Canada. “CDL Nuclear Technologies is a trusted name in private cardiology and nuclear imaging, and today’s announcement underscores the confidence both organizations have in Flyrcado’s potential. This agreement helps establish the foundation needed to support GE HealthCare’s vision for Flyrcado’s growth in outpatient cardiac PET imaging and reinforces our commitment to innovation and patient-centered care.”
Health Technology Insights: Distalmotion Teams Up with First Citizens Bank for Flexible Surgery Tech Financing
“We’re proud that CardioNavix will be the first distributor to bring Flyrcado to private practice cardiology,” said Lon Wilson, CEO of CDL Nuclear Technologies. “Through our nearly 225 customer sites, CDL and CardioNavix support around 220,000 patient procedures each year with end-to-end cardiac PET solutions—and that number continues to grow. Together with GE HealthCare, we’re helping more providers bring advanced cardiac PET to patients in both private office-based settings and hospitals.”
The DSA supports GE HealthCare’s long-term strategy to build the capabilities necessary for Flyrcado’s success in outpatient settings. Initial roll-out will begin in late 2025 and accelerate into broader expansion throughout 2026.
GE HealthCare’s Pharmaceutical Diagnostics division is a global leader in imaging agents used to support around 130 million procedures per year globally, equivalent to four patient procedures every second. Its Molecular Imaging portfolio combines established proprietary products across cardiology, neurology and oncology, with an innovative pipeline, all aimed at enabling better informed diagnosis and monitoring for improved therapy decision making and clinical outcomes.
Health Technology Insights: AEYE Health Names Yonatan Raz-Fridman as Chief Business Officer
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source- businesswire
